Intra-operative autologous blood management

Transfusion and Apheresis Science

Volumn 27, Issue 1, 2002, Pages 73-81

  McMillan, D ^a   Dando, H ^a   Potger, K ^a   Southwell, J ^a   O'shaunghnessy K ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CITRIC ACID; HEMOGLOBIN; HEPARIN; HEPARIN LYASE; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; BLOOD STORAGE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEVICE; DOSE RESPONSE; DRUG HALF LIFE; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEMATOCRIT; HEMODILUTION; HEMOSTASIS; HUMAN; INTRAOPERATIVE PERIOD; LABORATORY TEST; META ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN TIME; THORAX SURGERY; THROMBOCYTOPENIA;

BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION, AUTOLOGOUS; HEMATOLOGIC TESTS; HEMORRHAGE; HUMANS; INTRAOPERATIVE CARE;

EID: 0036087608     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(02)00028-9     Document Type: Article

References (35)

1. Autotransfusion in cardiac surgery
2. Controversies in transfusion medicine. Is autologous blood transfusion worth the cost?
3. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass
4. Autotransfusion: Historical review and preliminary report on a new method
5. Influence of different autotransfusion devices on the quality of salvaged blood
6. Pulmonary implications of filtering various mediators of morbidity found in salvaged blood
7. A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. International Study of Perioperative Transfusion (ISPOT) Investigators
8. Bleeding after cardiopulmonary bypass
9. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits
10. Acute platelet-rich plasmapheresis for cardiac surgery
11. Quality of harvested autologous platelets compared with stored donor platelets for use after cardiopulmonary bypass procedures
12. Platelet-leukocyte plasmapheresis attenuates the deleterious effects of cardiopulmonary bypass
13. Influence of acute preoperative plasmapheresis on platelet function in cardiac surgery
14. Plateletpheresis before redo CABG diminishes excessive blood transfusion
15. Does perioperative autologous blood componant therapy demonstrate clinical benefits in patients undergoing orthopedic surgery
16. Platelet function in cardiac surgery: Influence of temperature and aprotinin
17. Monitoring of hemostasis in cardiac surgical patients: Impact of point-of-care testing on blood loss and transfusion outcomes
18. Bleeding complications associated with cardiopulmonary bypass
19. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation
20. Heparinless partial cardiopulmonary bypass for the repair of aortic trauma
21. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations
22. Future directions in utilization review: The role of transfusion algorithms
23. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
24. Is hemoglobin level alone a reliable predictor of outcome in the severely anemic surgical patient?
25. Activated coagulation time of whole blood
26. Substrate specificity of the heparin lyases from Flavobacterium heparinum
27. On-site prothrombin time, activated partial thromboplastin time, and platelet count. A comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery
28. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis
29. Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer
30. Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy
31. Determinants of blood utilization during myocardial revascularization
32. On the need for improved transfusion indicators in cardiac surgery
33. Lack of adherence to the guidelines on the use of fresh frozen plasma
34. Guiding the decision to transfuse
35. Blood transfusion in adults: Description of a quality assurance program